The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin
Open accessAbstract
Objectives The purpose of this study was to assess the impact on cardiovascular and adverse events of attaining low-density lipoprotein cholesterol (LDL-C) levels <50 mg/dl with rosuvastatin in apparently healthy adults in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial.Background The safety and magnitude of cardiovascular risk reduction conferred by treatment to LDL-C levels below current recommended targets remain uncertain.Methods A cohort of 17,802 apparently healthy men and women with high-sensitivity C-reactive protein ≥2 mg/l and LDL-C <130 mg/dl were randomly allocated to rosuvastatin 20 mg daily or placebo, and followed up for all-cause mortality, major cardiovascular events, and adverse events. In a post-hoc analysis, participants allocated to rosuvastatin were categorized as to whether or not they had a follow-up LDL-C level <50 mg/dl.Results During a median follow-up of 2 years (range up to 5 years), rates of the primary trial endpoint were 1.18, 0.86, and 0.44 per 100 person-years in the placebo group (n = 8,150) and rosuvastatin groups without LDL-C <50 mg/dl (n = 4,000) or with LDL-C <50 mg/dl (n = 4,154), respectively (fully-adjusted hazard ratio: 0.76; 95% confidence interval: 0.57 to 1.00 for subjects with no LDL-C <50 mg/dl vs. placebo and 0.35, 95% confidence interval: 0.25 to 0.49 for subjects attaining LDL-C <50 mg/dl; p for trend <0.0001). For all-cause mortality, corresponding event rates were 0.67, 0.65, and 0.39 (p for trend = 0.004). Rates of myalgia, muscle weakness, neuropsychiatric conditions, cancer, and diabetes mellitus were not significantly different among rosuvastatin-allocated participants with and without LDL-C <50 mg/dl.Conclusions Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein ≥2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the greater the absolute LDL-C reduction, the greater the CV risk reduction [35,36,50,115].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [115]
In the citing paper
“There is also evidence suggesting that lowering LDL-C beyond the goals that were set in the previous EAS/ESC guidelines is associated with fewer CVD events. 126”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [126]
In the citing paper
“There is also evidence suggesting that lowering LDL-C beyond the goals that were set in the previous EAS/ESC guidelines is associated with fewer CVD events.126”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010
Self-citationNakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., Nakaya, N., Nishimoto, S., Muranaka, M., Yamamoto, A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69472-5 · Cited by 941
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
Air Force/Texas Coronary Atherosclerosis Prevention Study
佐々木, 淳. (2008) · Japanese journal of clinical medicine · Cited by 411
Wiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.064 · Cited by 340
Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program.
Yano, K., REED, D. M., & MacLean, C. J. (1989) · Stroke · doi:10.1161/01.str.20.11.1460 · Cited by 310
Statins and cancer: A systematic review and meta-analysis
Kuoppala, J., Lamminpää, A., & Pukkala, . (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.025 · Cited by 290
O'Keefe, J. H., & Cordain, L. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.1.101 · Cited by 289
Metabolic and physiologic improvements from consuming a paleolithic, hunter-gatherer type diet
Frassetto, L. A., Schloetter, M. C., Mietus-Synder, M., Morris, R. C., & Sébastian, A. (2009) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2009.4 · Cited by 282
Shepherd, J., Blauw, G. J., & Murphy, M. B. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00040-0 · Cited by 275
Abifadel, M., Rabès, J., Devillers, M., Münnich, A., Erlich, D., Junien, C., Varret, M., & Boileau, C. (2009) · Human Mutation · doi:10.1002/humu.20882 · Cited by 260
Ebrahim, S. B. J., Sung, J., Song, Y., Ferrer, R. L., Lawlor, D. A., & Smith, G. D. (2006) · BMJ · doi:10.1136/bmj.38855.610324.80 · Cited by 187
LaRosa, J. C., Grundy, S. M., Kastelein, J. J. P., Kostis, J. B., & Greten, H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.102 · Cited by 147
Verhulst, A., D’Haese, P. C., & Broe, M. E. D. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000136778.32499.05 · Cited by 134
Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer
Alsheikh-Ali, A. A. A., Trikalinos, T. A., Kent, D. M., & Karas, R. H. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.037 · Cited by 113
Statin Use and Incident Nuclear Cataract
Klein, R., Klein, R., Lee, K. E., & Grady, L. M. (2006) · JAMA · doi:10.1001/jama.295.23.2752 · Cited by 110
Gerson, R. J., MacDonald, J. S., Alberts, A. W., Chen, J., Yudkovitz, J. B., Greenspan, M. D., Rubin, L. F., & Bokelman, D. L. (1990) · Experimental Eye Research · doi:10.1016/0014-4835(90)90012-j · Cited by 101
Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?
Gaist, D., Rodríguez, L. A. G., Huerta, C., Hallas, J., & Sindrup, S. H. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000248 · Cited by 93
Psychiatric Adverse Reactions with Statins, Fibrates and Ezetimibe
Tatley, M. V., & Savage, R. L. (2007) · Drug Safety · doi:10.2165/00002018-200730030-00003 · Cited by 85
Shepherd, J., Vidt, D. G., Miller, E., Harris, S., & Blasetto, J. W. (2007) · Cardiology · doi:10.1159/000100908 · Cited by 84
Corrao, G., Zambon, A., Bertù, L., Botteri, E., Leoni, O., & Contiero, P. (2004) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2003.013409 · Cited by 73
Risk of Cataract in Patients Treated With Statins
Schlienger, R. G., Haefeli, W. E., Jick, H., & Meier, C. R. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.16.2021 · Cited by 69
Harris, M. L., Bron, A. J., Brown, N., KEECH, A. C., Wallendszus, K., Armitage, J., MacMahon, S. W., Snibson, G. R., & Collins, R. (1995) · British Journal of Ophthalmology · doi:10.1136/bjo.79.11.996 · Cited by 63
Tikkanen, M. J., Holme, I., Cater, N. B., Szarek, M. J., Færgeman, O., Kastelein, J. J. P., OLSSON, A. G., Larsen, M. L., Lindahl, C., & Pedersen, T. R. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.029 · Cited by 57
Advances in Understanding Drug-Induced Neuropathies
Peltier, A., & Russell, J. W. (2006) · Drug Safety · doi:10.2165/00002018-200629010-00002 · Cited by 51
Pitt, B. (2005) · New England Journal of Medicine · doi:10.1056/nejme058052 · Cited by 47
Statin Use and Cancer Risk: An Epidemiologic Review
Friis, S., & Olsen, J. H. (2006) · Cancer Investigation · doi:10.1080/07357900600705532 · Cited by 27
Wiviott, S. D., Mohanavelu, S., Raichlen, J. S., Cain, V. A., Nissen, S. E., & Libby, P. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.02.040 · Cited by 23
Statins, lack of energy and ubiquinone
Reidenberg, M. M. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02359.x · Cited by 12
Ben‐Yehuda, O., & DeMaria, A. N. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.001 · Cited by 10
Cited by
Sorted by citations
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., II, Goldstein, L. B., Chin, C. C., Tannock, L. R., Miller, M. J., Raghuveer, G., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 790
Metadata
- Authors
- Hsia, J., MacFadyen, J. G., Monyak, J., & Ridker, P. M.
- Affiliations
- AstraZeneca (United States) (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Hsia, Judith
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 57
- Issue
- 16
- Pages
- 1666-1675
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W166112863
- Cited by
- 231
- References
- 41
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 12 · 2021: 8 · 2020: 10 · 2019: 15 · 2018: 14 · 2017: 23 · 2016: 23 · 2015: 30 · 2014: 20 · 2013: 22 · 2012: 19
- FWCI
- 23.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca LP
- AstraZeneca
- Novartis
- Merck
- Abbott
- Roche
- Sanofi-Aventis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- rosuvastatin, LDL cholesterol, cardiovascular risk reduction, high-sensitivity C-reactive protein, JUPITER trial, statin safety, all-cause mortality, major adverse cardiovascular events, myalgia, diabetes mellitus, cancer, neuropsychiatric adverse effects, hypercholesterolemia, inflammation, cardiovascular disease prevention
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Humans, Cholesterol, LDL, Male, Middle Aged, Pyrimidines, Sulfonamides, Cohort Studies, Biomarkers, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
